Treatment of Pain Syndromes with Venlafaxine

Pharmacotherapy

Volumn 24, Issue 5 I, 2004, Pages 621-629

  Grothe, Dale R ^a   Scheckner, Brian ^a   Albano, Dominick ^a  

^a PFIZER INC   (United States)

Author keywords

Antidepressants; Chronic pain; Fibromyalgia; General anxiety disorder; Headache; Major depressive disorder; Neuropathic pain; Postmastectomy pain syndrome; Venlafaxine

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; METIROSINE; NALOXONE; OPIATE ANTAGONIST; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ABDOMINAL PAIN; AGITATION; ANXIETY DISORDER; ARTHRALGIA; BACKACHE; CANCER PAIN; CLINICAL MEDICINE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FIBROMYALGIA; HEADACHE; HUMAN; INSOMNIA; MAJOR DEPRESSION; META ANALYSIS; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; PAIN; POSTMASTECTOMY PAIN SYNDROME; PRIMARY HEALTH CARE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SWEATING; TREATMENT OUTCOME; XEROSTOMIA;

ANALGESICS; ANIMALS; ANXIETY DISORDERS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PAIN; PAIN, POSTOPERATIVE; RANDOMIZED CONTROLLED TRIALS;

EID: 2342612800     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.6.621.34748     Document Type: Review

References (59)

1. Kroenke K, Price RK. Symptoms in the community. Prevalence, classification, and psychiatric comorbidity. Arch Intern Med 1993;153:2474-80.
2. Krishnan KR, France RD, Pelton S, McCann UD, Davidson J, Urban BJ. Chronic pain and depression. II. Symptoms of anxiety in chronic low back pain patients and their relationship to subtypes of depression. Pain 1985;22:289-94.
3. Krishnan KR, France RD, Pelton S, McCann UD, Davidson J, Urban BJ. Chronic pain and depression. I. Classification of depression in chronic low back pain patients. Pain 1985;22:279-87.
4. Kirmayer LJ, Robbins JM, Dworkind M, Yaffe MJ. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry 1993;150:734-41.
5. Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression [comment]. N Engl J Med 1999;341:1329-35.
6. Kroenke K, Spitzer RL, Williams JB, et al. Physical symptoms in primary care: predictors of psychiatric disorders and functional impairment. Arch Fam Med 1994;3:774-9.
7. Hudson JI, Mangweth B, Pope HG Jr, et al. Family study of affective spectrum disorder. Arch Gen Psychiatry 2003;60:170-7.
8. Blackburn-Munro G, Blackburn-Munro RE. Chronic pain, chronic stress and depression: coincidence or consequence? J Neuroendocrinol 2001;13:1009-23.
9. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000;57:925-35.
10. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene [comment]. Science 2003;301:386-9.
11. Ohayon M, Schatzberg A. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 2003;60:39-47.
12. Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS. Chronic pain-associated depression: antecedent or consequence of chronic pain? A review. Clin J Pain 1997;13:116-37.
13. Nelson JC, Mazure CM, Bowers MB Jr, Jatlow P. A preliminary open study of the combination of fluoxetine and desipramine for rapid treatment of major depression [comment]. Arch Gen Psychiatry 1991;48:303-7.
14. Vestergaard P, Gram LF, Kragh-Sorensen P, Bech P, Reisby N, Bolwig TG. Therapeutic potentials of recently introduced antidepressants: Danish university antidepressant group. Psychopharmacol Ser 1993;10:190-8.
15. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41.
16. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404.
17. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affective Disord 1999;56:171-81.
18. Silverstone PH, Entsuah R, Hackett D. Two items on the Hamilton depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine. Int Clin Psychopharmacol 2002;17:273-80.
19. Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998;7:11-17.
20. Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001;26:30-6.
21. Magni G. The use of antidepressants in the treatment of chronic pain: a review of the current evidence. Drugs 1991;42:730-48.
22. Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic nonmalignant pain: a meta-analysis of 39 placebo-controlled studies. [comment]. Pain 1992;49:205-19.
23. Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature. Harvard Rev Psychiatry 2000;7:257-77.
24. Egbunike IG, Chaffee BJ. Antidepressants in the management of chronic pain syndromes. Pharmacotherapy 1990;10:262-70.
25. Barkin RL, Fawcett J. The management challenges of chronic pain: the role of antidepressants. Am J Ther 2000;7:31-47.
26. Songer DA, Schulte H. Venlafaxine for the treatment of chronic pain [letter]. Am J Psychiatry 1996;153:737.
27. Taylor K, Rowbotham MC. Venlafaxine hydrochloride and chronic pain. Western J Med 1996;165:147-8.
28. Adelman LC, Adelman JU, Von Seggern R, Mannix LK. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: a retrospective study in a clinical setting. Headache 2000;40:572-80.
29. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-6.
30. Willis WD, Westlund KN. Neuroanatomy of the pain system and of the pathways that modulate pain. J Clin Neurophysiol 1997;14:2-31.
31. Sindrup SH, Jensen TS. Antidepressants in the treatment of neuropathic pain. In: Hanson PT, Fields HL, Hill RG, eds. Neuropathic pain: pathophysiology and treatment, progress in pain research and management, vol 12. Seattle, WA: IASP Press, 2001:169-83.
32. Lang E, Hord AH, Denson D. Venlafaxine hydrochloride (Effexor) relieves thermal hyperalgesia in rats with an experimental mononeuropathy. Pain 1996;68:151-5.
33. Marchand F, Alloui A, Chapuy E, et al. Evidence for a monoamine-mediated, opioid-independent, antihyperalgesic effect of venlafaxine, a nontricyclic antidepressant, in a neurogenic pain model in rats. Pain 2003;103:229-35.
34. Schreiber S, Backer MM, Pick CG. The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms. Neurosci Lett 1999;273:85-8.
35. Marchand F, Alloui A, Pelissier T, et al. Evidence for an antihyperalgesic effect of venlafaxine in vincristine-induced neuropathy in rat. Brain Res 2003;980:117-20.
36. Uyar M, Onal A, Dogru A, Soykan N. The antinociceptive effect of tramadol-venlafaxine combination on the paw withdrawal threshold in a rat model of neuropathic pain. Methods Find Exp Clin Pharmacol 2003;25:361-5.
37. Enggaard TP, Klitgaard NA, Gram LF, Arendt-Nielsen L, Sindrup SH. Specific effect of venlafaxine on single and repetitive experimental painful stimuli in humans. Clin Pharmacol Ther 2001;69:245-51.
38. Bradley RH, Barkin RL, Jerome J, DeYoung K, Dodge CW. Efficacy of venlafaxine for the long-term treatment of chronic pain with associated major depressive disorder. Am J Ther 2003;10:318-23.
39. Meoni P. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. J Clin Psychiatry 2001;62:888-93.
40. Kunz N, Goli V, Entsuah A, Rudolph R. Effect of venlafaxine extended release on diabetic neuropathic pain. Presented as a poster at the annual meeting of the American Psychiatric Association, Chicago, IL, May 13-18, 2000.
41. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003;60:1284-9.
42. Demitrack MA, Kunz NR, Entsauh R. Use of venlafaxine for chronic pain associated with postherpetic neuralgia. Presented as a poster at the annual meeting of the American Psychiatric Association, San Francisco, CA, May 17-22, 2003.
43. Tasmuth T, Haertel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain London 2002;6:17-24.
44. Galer BS. Neuropathic pain of peripheral origin: advances in pharmacologic treatment. Neurology 1995;45:S17-25, S35-6.
45. Erdemoglu AK. Effectiveness of venlafaxine in symptomatic treatment of diabetic neuropathy [abstr]. Ann Neurol 2002;52:S64.
46. Davis JL, Smith RL. Painful peripheral diabetic neuropathy treated with venlafaxine HCl extended release capsules [comment]. Diabetes Care 1999;22:1909-10.
47. Lithner F. Venlafaxine in treatment of severe painful peripheral diabetic neuropathy. Diabetes Care 2000;23:1710-11.
48. Kiayias JA, Vlachou ED, Lakka-Papadodima E. Venlafaxine HCl in the treatment of painful peripheral diabetic neuropathy [comment]. Diabetes Care 2000;23:699.
49. Sumpton JE, Moulin DE. Treatment of neuropathic pain with venlafaxine. Ann Pharmacother 2001;35:557-9.
50. Pernia A, Mico JA, Calderon E, Torres LM. Venlafaxine for the treatment of neuropathic pain. J Pain Symptom Manage 2000;19:408-10.
51. Durand JP, Goldwasser F. Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine. Anticancer Drugs 2002;13:777-80.
52. Kathpal GS. Role of SSRIs in the management of migraine. Headache Q Curr Treat Res 1998;9:265-6.
53. Nascimento ED. Prophylaxis of migraine: open study with venlafaxine in 42 patients. Arquivos de Neuro-Psiquiatria 1998;56:744-6.
54. Diamond S. Efficacy and safety profile of venlafaxine in chronic headache. Headache Q Curr Treat Res 1995;6:212-14.
55. Dwight MM, Arnold LM, O'Brien H, Metzger R, Morris-Park E, Keck PE Jr. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 1998;39:14-17.
56. Reuben S, Lurie S, Deluca P, Charles GS. Efficacy of the perioperative administration of venlafaxine XR in the prevention of postmastectomy pain syndrome]. Presented at the 27th meeting of the American Society of Regional Anesthesia and Pain Medicine, Chicago, IL, April 25-28, 2002.
57. Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethylcyclohexanol derivative. Biochem Pharmacol 1986;35:4493-7.
58. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991;23:191-9.
59. Wyeth Pharmaceuticals. Effexor XR (venlafaxine) package insert. Philadelphia, PA; 2003.